Results 161 to 170 of about 2,061,986 (268)

Olaparib synergy screen reveals Exemestane induces replication stress in triple‐negative breast cancer

open access: yesMolecular Oncology, EarlyView.
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh   +5 more
wiley   +1 more source

Guanosine-Based Supramolecular Particles for Enhanced Drug and Gene Delivery in Cell Culture. [PDF]

open access: yesACS Appl Bio Mater
Negrón LM   +6 more
europepmc   +1 more source

Effect of Aflatoxin B1on Cell Cultures [PDF]

open access: bronze, 1965
Janis Gabliks   +3 more
openalex   +1 more source

Pericytes change function depending on glioblastoma vicinity: emphasis on immune regulation

open access: yesMolecular Oncology, EarlyView.
Pericytes alter their transcriptome depending on their proximity to the tumor core. In the tumor core, pericytes display a more active state with higher communication strength but with lower immune activation potential and a shift toward extracellular matrix production.
Carolina Buizza   +5 more
wiley   +1 more source

Plasma-activated water modulates taxanes production and phenylalanineammonia-lyase activity in Taxus baccata cell culture. [PDF]

open access: yesPLoS One
Fathali Tehrani MH   +5 more
europepmc   +1 more source

RKIP overexpression reduces lung adenocarcinoma aggressiveness and sensitizes cells to EGFR‐targeted therapies

open access: yesMolecular Oncology, EarlyView.
RKIP, a metastasis suppressor protein, modulates key oncogenic pathways in lung adenocarcinoma. In silico analyses linked low RKIP expression to poor survival. Functional studies revealed RKIP overexpression reduces tumor aggressiveness and enhances sensitivity to EGFR‐targeted therapies, while its loss promotes resistance.
Ana Raquel‐Cunha   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy